

Alma Mater Studiorum Università di Bologna  
Archivio istituzionale della ricerca

Adult lifetime body mass index trajectories and endometrial cancer risk

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

Dalmartello, M., Vermunt, J., Negri, E., Levi, F., La Vecchia, C. (2022). Adult lifetime body mass index trajectories and endometrial cancer risk. *BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY*, 129(9), 1521-1529 [10.1111/1471-0528.17087].

*Availability:*

This version is available at: <https://hdl.handle.net/11585/901090> since: 2022-11-09

*Published:*

DOI: <http://doi.org/10.1111/1471-0528.17087>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

(Article begins on next page)

DR. MICHELA DALMARTELLO (Orcid ID : 0000-0001-8764-9299)

Article type : Research Article

## ADULT LIFETIME BODY MASS INDEX TRAJECTORIES AND ENDOMETRIAL CANCER RISK

Michela Dalmartello<sup>1</sup>, Jeroen Vermunt<sup>2</sup>, Eva Negri<sup>1,3,4</sup>, Fabio Levi<sup>5</sup>, Carlo La Vecchia<sup>1</sup>

<sup>1</sup>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

<sup>2</sup>Department of Methodology and Statistics, Tilburg University, Tilburg, The Netherlands.

<sup>3</sup>Department of Humanities, Università Telematica Pegaso, Naples, Italy.

<sup>4</sup>Department of Medical and Surgical Sciences, University of Bologna, Italy.

<sup>5</sup>Department of Epidemiology and Health Services research, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.

### CORRESPONDING AUTHOR

Michela Dalmartello, MA MSc PhD

Department of Clinical Sciences and Community Health, University of Milan

Via A. Vanzetti, 5, 20133 Milan, Italy

Phone: +39 0250320880

fax: +39 0250320866

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/1471-0528.17087](#)

This article is protected by copyright. All rights reserved

email: Michela.dalmartello@unimi.it

ORCID: 0000-0001-8764-9299

RUNNING TITLE: Body mass index trajectories and endometrial cancer risk

1 ABSTRACT

2 *Objective:* To identify body mass index (BMI) trajectories in adult life and to examine their association  
3 with endometrial cancer (EC) risk, also exploring whether relations differ by HRT use.

4 *Design:* Pooled analysis of two case control studies.

5 *Setting:* Italy and Switzerland.

6 *Population:* A total of 458 EC cases and 782 controls.

7 *Methods:* We performed a latent class growth model in order to identify homogenous BMI trajectories  
8 over 6 decades of age, with a polynomial function of age. Odds Ratios (ORs) and the corresponding 95%  
9 confidence intervals (CI) for EC risk were derived through a multiple logistic regression model, correcting  
10 for classification error.

11 *Main outcome measures:* The relation of BMI trajectories with endometrial cancer.

12 *Results:* We identified 5 BMI trajectories. Compared with women in the 'Normal weight-stable' trajectory,  
13 a reduction by about 50% in the risk of EC emerged for those in the 'Underweight increasing to normal  
14 weight' (95% CI=0.28-0.99). The 'Normal weight increasing to overweight' and the 'Overweight-stable'  
15 trajectories were associated to, respectively, an excess of 3% (95% CI=0.66-1.60) and of 71% (95% CI=  
16 1.12-2.59) in cancer risk. The OR associated to the trajectory 'Overweight increasing to obese' was 2.03  
17 (95% CI= 1.31-3.13). Stronger effects emerged among HRT never users (OR= 2.19 for the 'Overweight-  
18 stable' trajectory and OR=2.49 for the 'Overweight increasing to obese' trajectory).

19 *Conclusions:* Our study suggests that longer exposure to overweight and obesity across lifetime is  
20 associated with an increased risk of endometrial cancer. Weight during adulthood also appears to play an  
21 important role.

22 *Keywords:* Endometrial cancer; body mass index; latent class growth models; body mass index  
23 trajectories; prevention.



## 24 INTRODUCTION

25 Overweight and obesity are leading risk factors for disease and death globally. Elevated body mass index  
26 (BMI) has been associated with an increased risk of cardiovascular diseases and type 2 diabetes, but also  
27 selected neoplasms (1). One of the major public health concern worldwide has been the continuing  
28 increases in obesity prevalence over the past decades and its consequences on chronic diseases.

29 Obesity is strongly associated with an increased risk of endometrial cancer (EC) (2, 3). Most of the main  
30 recognized risk factors for EC act via an excessive and prolonged exposure to oestrogens unopposed by  
31 progesterone. In post menopause, the adipose tissue provides endogenous oestrogens through  
32 aromatization of androgens secreted by adrenal glands. Moreover, decreased sex hormone binding  
33 globulin (SHBG) concentration leads to increased bioavailable oestrogens (4). Another relevant risk factor  
34 for EC is hormonal replacement therapy (HRT), which provides exogenous oestrogens, particularly when  
35 not opposed by progestin. With the substantial reduction in HRT use over the last two decades (5), body  
36 size has achieved a greater impact on EC risk.

37 The relationship between BMI and EC risk has been investigated. Most studies, however, rely on cross-  
38 sectional exposure information on BMI, typically at recruitment. The relation between weight change over  
39 time and EC risk is less well understood, and evidence on the cumulative impact of overweight and  
40 obesity during the life course on EC risk is scarce. Moreover, insights into whether the effect of body mass  
41 lifetime trajectories on the risk for EC differs by HRT use are still limited. Given that the carcinogenic  
42 processes usually take several decades, it is important to determine the possible impact of patterns of  
43 BMI lifetime changes on EC risk.

44 The aim of this study is to identify BMI trajectories in adult life and to examine their association with EC  
45 risk pooling data from two case control studies from Italy and Switzerland (6, 7). We also explored in  
46 detail whether relations differed by HRT use.

## 47 METHODS

### 48 *Study population*

49 A case-control study on EC was conducted between 1988 and 1998 in the Swiss Canton of Vaud and in the  
50 metropolitan Milan, Northern Italy. In Vaud, cases recruitment was population based, since identified  
51 cases were cross checked with incident cases reported to the local cancer registry. Overall, more than  
52 80% of identified cases were interviewed. In Milan, case recruitment was hospital based, because the area  
53 was not covered by cancer registration schemes. Controls were women aged 75 years or less who were

admitted to the same networks of hospitals of cases, with a primary diagnosis unrelated to any of the recognized risk factors for EC or to any long-term modification in diet. Women admitted for gynaecologic, hormonal, metabolic or neoplastic conditions, or with a history of hysterectomy were also excluded. Less than 5% of patients refused to participate. Overall, 466 cases of histologically confirmed EC and 792 controls were included.

Centrally trained interviewers administered the same structured questionnaire, in the same settings, to cases and controls. The questionnaire included information on demographics, a validated food frequency questionnaire (FFQ), a problem-oriented medical and reproductive history, including ever use of oral contraceptives (OC) or HRT. Patients were not involved in the development of the research.

### *BMI assessment*

The questionnaire collected information on current height and weight at the following ages, if applicable: 20-29, 30-39, 40-49, 50-59, 60-69, and 70-74 years. Therefore, repeated weight measures were collected for each subject from 20-29 years up to their current age. BMI was computed at each time point as weight divided by squared height ( $\text{kg}/\text{m}^2$ ). Current height was used in each calculation. BMI was then categorized in underweight ( $<18.5$ ), normal weight ( $18.5\text{--}24.9$ ), overweight ( $25.0\text{--}29.9$ ), and obese ( $\geq 30.0$ ).

### *Statistical analysis*

We performed a latent class growth model (LCGM) in order to identify homogenous BMI trajectories over 6 decades of age, with a polynomial function of age. The LCGM identifies latent classes of BMI that differ in the initial state and in the way they changes over time. The model evaluates similarities in BMI measurements over time so that individuals in the same class present similar trajectories of BMI changes. The relation between latent classes and BMI was specified via an ordinal regression model. Class parity was determined by subsequently increasing the number of latent classes from 1 (where all individuals belong to the same trajectory) until the value of the Bayesian information criterion (BIC) ceased to monotonically decrease or until the last solution according to BIC with a minimum of 5% of subjects in each latent class. We also checked coherence with other studies about BMI trajectory groups that used between four and six groups (8-12). Multiple LCGM with different trajectory shapes including linear, quadratic and cubic parameters for age were tested, using BIC and Wald test for each age term to select optimal shapes.

BMI trajectories were named and interpreted according to the estimated values for their evolution over ages and conditional distribution of BMI (class-specific response probabilities) were reported. In order to

84 complement the description of the BMI trajectories, we also examined their associations with a selected  
85 set of variables.

86 In a second step, subjects were assigned to latent classes based on their posterior class membership  
87 probabilities, obtained from the estimated parameters of the LCGM model and their observed responses.  
88 Proportional allocation was chosen to permit a “soft” classification, assigning subjects to each class with a  
89 weight equal to their posterior membership probability for that class.

90 In a third step, Odds Ratios (ORs) and the corresponding 95% confidence intervals (Cis) for EC risk were  
91 derived through multiple logistic regression models using the class assignments to evaluate the effect of  
92 BMI trajectories on the risk of EC. To account for known and potential risk factors, the model included  
93 terms for age, country, education, diabetes, family history of EC, age at menarche, menopausal status,  
94 parity, ever OC use, ever HRT use and smoking. The classical approach, which first identifies latent classes,  
95 then assigns subject to each class and finally builds the prediction model, underestimates the associations  
96 between the outcome and the class membership (13). As classification errors occur even with  
97 proportional assignment (14), we used a maximum likelihood-based correction method which  
98 incorporates uncertainty about classification in the estimation procedure and performs best with  
99 categorical outcomes (13).

100 We excluded from the analysis subjects with missing information on height or weight at every time point  
101 (n=18), leading to a total of 458 cases and 782 controls. Sparse missing values in BMI measurements were  
102 not excluded in the analysis, yielding maximum likelihood estimates under MAR missingness assumption.  
103 To assess the robustness of the selected latent class growth model, we compared it with the results  
104 obtained on complete cases only. A few (<5%) missing values on adjustment factors were replaced by the  
105 most frequent response according to age group and country. (13)

106 In a latter analysis, we assessed the risk of EC according to BMI trajectories in strata of HRT ever  
107 use. Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA), RStudio version  
108 1.2.5019 (RStudio, Inc., Boston, Massachusetts, USA) and Latent Gold 6.0 (Vermunt & Magidson, 2021)  
109 statistical software.

## 110 RESULTS

111 The study population is described in Table S1. Controls were somewhat younger (11.3% vs 4.2% women  
112 under 45 years of age), had a higher proportion of women with age at menarche >15 (14.1% vs 9.0%),  
113 more frequent use of OC (17.3% vs 10.5%) and less frequent use of HRT (15.5% vs 22.9%).

#### 114 *BMI trajectories over adult lifetime*

115 We identified 5 BMI trajectories, conceived as latent classes with a different initial body size and a  
116 different evolution over life course. The best form of the relationship between BMI and time (i.e., age)  
117 was a cubic function, i.e., BMI increases over time but proportionally strongly over elderly ages.

118 Table 1 presents BMI trajectories, i.e., the evolution of BMI over time according to the five latent classes.

119 We labelled the first one 'Underweight increasing to normal weight' trajectory, because the prevalence of  
120 underweighted subjects was highest up to their '40, and the proportion of normal weighted gradually  
121 increased over time. During their '70-'80, the proportion of underweighted subjects slightly increased.  
122 Subjects in the 'Normal weight-stable' trajectory showed a constant permanence in the normal weight  
123 category of BMI over adult lifetime. Subjects in the 'Normal weight increasing to overweight' were in the  
124 normal weight range up to their middle age when they gradually turned to an overweight status that was  
125 maintained over their older years. The 'Overweight-stable' trajectory presented a change between their  
126 20-'30' and their '30-'40 where the proportion of normal weighted shifted towards overweight. More  
127 than 80% of the subjects in this trajectory were overweight from their '30 on. A constant increase over  
128 time in obese subjects was also reported. The 'Overweight increasing to obese' trajectory had the highest  
129 proportion of obese subject since age '20-'30, with a steady increase of subjects in the highest category of  
130 BMI.

131 Table 2 reports the conditional marginal distribution of BMI in the 5 latent classes over the whole period.

132 The 'Underweight increasing to normal weight' trajectory (estimated size=8.3% of subjects) was mainly  
133 composed by subjects with BMI<25. In the 'Normal weight-stable' class (estimated size=43.2% of subjects)  
134 more of 93% of subjects were in the range 18.5-<25. In the 'Normal weight increasing to overweight' class  
135 (estimated size=23.1% of subjects), 57% of subject had normal BMI. More than 74% of subjects in the  
136 'Overweight-stable' class were in the BMI range 25-30 (estimated size for this class=13.7% of subjects).  
137 People in the 'Overweight increasing to obese' class (estimated size=11.8% of subjects) reported BMI  
138 from 18.5 on, with a gradual increase in conditional probabilities up to the highest category of BMI that  
139 was composed by more than 56% of subjects.

140 The latent BMI trajectories showed specific traits in subjects' demographics and health/lifestyle  
141 characteristics (Table 3). Women in trajectories associated to lower BMI tended to be more educated  
142 (proportions of over 11 years of education were 34.1% and 33.9% respectively in the 'Underweight  
143 increasing to normal weight' and in the 'Normal weight-stable' trajectories, vs less than 22% in the other  
144 ones). Pluriparae were more likely to be in the 'Overweight-stable' and 'Overweight increasing to

145 obese' trajectories (more than 81% vs less than 77% in other trajectories). Less frequent use of OC and  
146 HRT was reported among women in the 'Overweight-stable' and 'Overweight increasing to obese'  
147 trajectories. Smokers were leaner.

#### 148 *BMI trajectories and EC risk*

149 Table 4 reports ORs and the corresponding 95% CIs for EC according to the identified BMI trajectories. A  
150 monotonic increase in the ORs emerged for higher BMI and longer exposure to higher BMI. When subjects  
151 in the trajectory in 'Normal weight-stable' were set as reference, a reduction by about 50% in EC risk  
152 emerged for those in the 'Underweight to normal' (95%CI=0.28-0.99). The 'Normal weight increasing to  
153 overweight' and the 'Overweight-stable' trajectories showed, respectively, an increase of 3% (95%  
154 CI=0.66-1.60) and of 71% (95% CI= 1.12-2.59) in cancer risk. The OR associated to the trajectory  
155 'Overweight increasing to obese' was 2.03 (95% CI= 1.31-3.13).

156 Table 4 also shows the results according to HRT use. No consistent trend in the BMI trajectories on EC risk  
157 emerged among ever HRT users. A monotonic increase in the ORs among HRT never users emerged, as in  
158 the general case. Stronger associations emerged with trajectories related to higher BMI: OR was 2.19  
159 (95% CI: 1.36-3.51) for the 'Overweight-stable' trajectory and 2.49 (95% CI=1.56-3.99) for the 'Overweight  
160 increasing to obese' trajectory. No significant difference in risk emerged for the 'Underweight increasing  
161 to normal weight' and the 'Normal weight to overweight', with respect to the 'Normal weight-stable'  
162 trajectory.

#### 163 DISCUSSION

##### 164 *Main findings*

165 The results of this study confirm not only a role of elevated BMI in the aetiology of EC but also the impact  
166 of duration of exposure across lifetime. A longer exposure to overweight and obesity was associated with  
167 an increased risk of EC and the level of weight during adulthood also seemed to play an important role. In  
168 general, greater BMI was associated to higher cancer risk, even within the low to normal reference range  
169 for BMI. The difference in risk between the 'Underweight to normal weight' and 'Normal weight'  
170 trajectories confirms that lean women have the lowest risk. The trajectories 'Normal to overweight' and  
171 'Overweight' displayed similar BMI composition after their '60, but in the last group the over  
172 representation of overweight people started earlier. The difference in risk of EC between these two  
173 groups indicates that women exposed to prolonged overweight/obesity during adulthood have higher  
174 risk.

176 These results are consistent with those reported in literature (15-29). Excess adiposity leads to hormonal  
177 and metabolic perturbations by producing oestrogen through the aromatization of androgens from  
178 adrenals to oestrogens in the adipose tissue (29). This is the main source of oestrogens in post-  
179 menopausal women (4, 7). Adipose tissue also increases levels of insulin and insulin-like growth factor 1  
180 (IGF-1), which reduce synthesis and circulating levels of SHBG (30). A systematic review reported that  
181 premenopausal obese women are exposed to prolonged unopposed oestrogens during early adulthood,  
182 resulting in an increased risk of EC (29). This is due to frequent anovulation in obese pre-menopausal  
183 women (31-36). The NIH-AARP Diet and Health Study cohort suggested that long term adiposity  
184 throughout adulthood was associated with increased risk of EC, beyond current adiposity (18). A  
185 longitudinal study from the United States reported that the intensity of overweight over time was  
186 associated to additional risk and found a dose-risk relationship. The authors suggested that earlier and  
187 long term exposure to overweight are likely related to mechanisms associated with increased risk of  
188 cancer, such as chronic inflammation, oxidative DNA damage, and mainly alterations in endogenous  
189 hormone metabolism (16). Diabetes is a consequence of overweight and obesity, but it is also  
190 independently related to EC risk (37).

191 Most studies analysed and reported separately single measures assessed at different ages. A study using a  
192 subset of our dataset (7) reported a greater effect of recent BMI but also a role of fat accumulated among  
193 overweight and obese women at diagnosis. However, only a few studies considered lifetime body size  
194 changes and EC risk (8, 16, 38). In particular, the Nurses' Health Study cohort analysed trajectories of body  
195 shape across the lifespan and several cancer risk with a similar methodological approach (8). There was a  
196 cubic relation of body shape with time, with a significant deviation from linearity, like we found for BMI.  
197 They identified 5 body shape trajectories that were similar to ours. Their Lean-moderate increase, Lean-  
198 marked increase, Medium-stable and Heavy-stable/increase were comparable, respectively to our Normal  
199 to overweight, Overweight, Normal, and Overweight to obese. The difference between their Lean-stable  
200 and our Under-to normal weight is at least in part ascribable to the different study population, and the  
201 higher weight of American women. Similarly to our results, they reported increasing hazard ratios for EC  
202 according to higher body size and its longer duration of exposure.

203 Consistently with the Nurses' Health Study cohort finding and previous evidence (5, 16, 18, 39-42), we  
204 observed that HRT use modified the association between BMI trajectories and EC risk. Among never HRT  
205 users, the positive association between BMI trajectories characterized by higher weight and its longer  
206 duration, and EC was monotonic. In contrast, no consistent trend of life trajectories of BMI emerged

among women who had used HRT. High levels of exogenous oestrogens in women using HRT may obscure the effect of overweight and obesity. Oestrone and serum estradiol levels among HRT users were reported to be around 3 to 4 times higher than among non-users, and about 1.4 to 1.6 times higher in obese women compared to normal weight women (43, 44).

#### *Strengths and Limitations*

Strengths of our analysis include the unique conceptual and methodological approach that allowed us to examine trajectories of BMI across the adult life course in a case-control setting, overpassing the well-known strategy that analyses separately different measurement at selected time point. Our analysis was more robust against the influence of confounding since studies based on a cross-sectional measure of BMI at a point in time are susceptible to confounding by previous body size. Working with categorized BMI allows to relax strong, and sometimes unrealistic, models assumption, such as normality of the distributions. LCGM has the advantage to not restrict the analysis on complete information. Incomplete information in our case derives from missing values and right censoring in subject younger than 74 years of age. We assigned subjects to trajectories using proportional assignment, lessening the classification errors derived from univocally assignment of women to the trajectory where the posterior membership probability was highest. To further minimize classification errors(14), we used a correction approach that incorporates uncertainty about classification in the estimation procedure and accounts for subjects contributing to the analysis with less than six measurement (i.e., subject with missing and/or with right censored information). We were also able to control for selected demographics and health, and lifestyle conditions, and had adequate power to assess the potential effect modification of HRT use.

Potential limitations of our study include information and selection bias. However, catchment area and the participation rates were similar between cases and controls. Controls were included in the studies according to a wide spectrum of conditions unrelated to cancer or the major risk factors for cancer, we excluded hysterectomised women from the control group (7), and overall participation was almost complete, thus reducing possible selection bias. Weight was self-reported, which might be subject to measurement error. It has been reported that particularly overweight and obese subjects tend to underestimate their body weight (45). However, little different recall is likely between cases and controls, given the same setting, and most women were unaware that elevated weight is a risk factor for EC. Moreover, categorizing BMI shall reduce potential misclassification. Still, our results need to be interpreted with cautions due to the relatively small sample size in some strata.

#### CONCLUSION

238 This study contributes to extend the accumulating evidence on the role of body size over adult life course  
239 on EC risk. Greater weight and longer exposure to higher BMI particularly among non HRT users is  
240 associated to an increased risk of EC. Given that the prevalence of unopposed HRT has decreased (46),  
241 excess body size is the leading preventable cause of EC. Prevention of weight gain across all weight  
242 categories, but particularly when leading to overweight and obesity, must be recommended, regardless of  
243 the age. Thus, it is never too late to control weight in order to reduce individual EC risk.

#### 244 AUTHORS' CONTRIBUTIONS

245 MD conducted data analysis and released the first draft. JV supervised data analysis and revised the  
246 manuscript. CLV designed the study and the data collection and revised the manuscript. EN revised data  
247 collection and managements and revised the manuscript. FL organized data collection and revised the  
248 manuscript. All authors approved the final version of the manuscript.

#### 249 ETHICS APPROVAL AND CONSENT TO PARTICIPATE

250 The participating studies were performed in accordance with laws, regulations and guidelines for the  
251 protection of human subjects (including consent from the participants) applicable at the time of study  
252 conduction, and in accordance with the Declaration of Helsinki.

#### 253 DATA AVAILABILITY

254 Data are available upon reasonable request.

#### 255 COMPETING INTEREST

256 The authors declare no competing interests.

#### 257 FUNDING

258 Study was supported by the AIRC Foundation and by the Swiss National Science Foundation grant  
259 32.9495.88.



## 260 REFERENCES

- 261 1. Prospective Studies C, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass  
262 index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.  
263 *Lancet*. 2009;373(9669):1083-96.
- 264 2. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer.  
265 *Gynecol Oncol*. 1991;41(1):1-16.
- 266 3. Report. WCRFAIfCRCUP. Food, Nutrition, Physical Activity, and the Prevention of Endometrial  
267 Cancer. . <http://www.dietandcancerreport.org>
- 268 4. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. *J*  
269 *Clin Endocrinol Metab*. 1973;36(2):207-14.
- 270 5. Horn-Ross PL, Canchola AJ, Bernstein L, Deapen D, Lacey JV, Jr., Lee E, et al. Body size over the  
271 life-course and the risk of endometrial cancer: the California Teachers Study. *Cancer Causes Control*.  
272 2016;27(12):1419-28.
- 273 6. Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, et al. Intrauterine devices  
274 and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. *Int*  
275 *J Cancer*. 2015;136(5):E410-22.
- 276 7. Levi F, La Vecchia C, Negri E, Parazzini F, Franceschi S. Body mass at different ages and subsequent  
277 endometrial cancer risk. *Int J Cancer*. 1992;50(4):567-71.
- 278 8. Song M, Willett WC, Hu FB, Spiegelman D, Must A, Wu K, et al. Trajectory of body shape across  
279 the lifespan and cancer risk. *Int J Cancer*. 2016;138(10):2383-95.
- 280 9. Andersen GS, Wibaek R, Kaestel P, Girma T, Admassu B, Abera M, et al. Body Composition Growth  
281 Patterns in Early Infancy: A Latent Class Trajectory Analysis of the Ethiopian iABC Birth Cohort. *Obesity*  
282 (Silver Spring). 2018;26(7):1225-33.
- 283 10. Fan B, Yang Y, Dayimu A, Zhou G, Liu Y, Li S, et al. Body Mass Index Trajectories During Young  
284 Adulthood and Incident Hypertension: A Longitudinal Cohort in Chinese Population. *J Am Heart Assoc*.  
285 2019;8(8):e011937.
- 286 11. Paynter L, Koehler E, Howard AG, Herring AH, Gordon-Larsen P. Characterizing long-term patterns  
287 of weight change in China using latent class trajectory modeling. *PLoS One*. 2015;10(2):e0116190.
- 288 12. Yang Y, Lynch BM, Dugue PA, Karahalios A, MacInnis RJ, Bassett JK, et al. Latent Class Trajectory  
289 Modeling of Adult Body Mass Index and Risk of Obesity-Related Cancer: Findings from the Melbourne  
290 Collaborative Cohort Study. *Cancer Epidemiol Biomarkers Prev*. 2021;30(2):373-9.

- 291 13. Bakk Z, Tekle FB, Vermunt JK. Estimating the Association between Latent Class Membership and  
292 External Variables Using Bias-Adjusted Three-Step Approaches. *Sociol Methodol*. 2013;43:272-311.
- 293 14. Bolck A, Croon M, Hagenaars J. Estimating latent structure models with categorical variables: One-  
294 step versus three-step estimators. *Polit Anal*. 2004;12(1):3-27.
- 295 15. Aarestrup J, Gamborg M, Tilling K, Ulrich LG, Sorensen TI, Baker JL. Childhood body mass index  
296 growth trajectories and endometrial cancer risk. *Int J Cancer*. 2017;140(2):310-5.
- 297 16. Arnold M, Jiang L, Stefanick ML, Johnson KC, Lane DS, LeBlanc ES, et al. Duration of Adulthood  
298 Overweight, Obesity, and Cancer Risk in the Women's Health Initiative: A Longitudinal Study from the  
299 United States. *PLoS Med*. 2016;13(8):e1002081.
- 300 17. Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al. Anthropometric  
301 factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective  
302 studies. *Ann Oncol*. 2015;26(8):1635-48.
- 303 18. Chang SC, Lacey JV, Jr., Brinton LA, Hartge P, Adams K, Mouw T, et al. Lifetime weight history and  
304 endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.  
305 *Cancer Epidemiol Biomarkers Prev*. 2007;16(4):723-30.
- 306 19. Han X, Stevens J, Truesdale KP, Bradshaw PT, Kucharska-Newton A, Prizment AE, et al. Body mass  
307 index at early adulthood, subsequent weight change and cancer incidence and mortality. *Int J Cancer*.  
308 2014;135(12):2900-9.
- 309 20. Hosono S, Matsuo K, Hirose K, Ito H, Suzuki T, Kawase T, et al. Weight gain during adulthood and  
310 body weight at age 20 are associated with the risk of endometrial cancer in Japanese women. *J Epidemiol*.  
311 2011;21(6):466-73.
- 312 21. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis.  
313 *Public Health*. 2015;129(7):872-80.
- 314 22. Liu Y, Warren Andersen S, Wen W, Gao YT, Lan Q, Rothman N, et al. Prospective cohort study of  
315 general and central obesity, weight change trajectory and risk of major cancers among Chinese women.  
316 *Int J Cancer*. 2016;139(7):1461-70.
- 317 23. Nagle CM, Marquart L, Bain CJ, O'Brien S, Lahmann PH, Quinn M, et al. Impact of weight change  
318 and weight cycling on risk of different subtypes of endometrial cancer. *Eur J Cancer*. 2013;49(12):2717-26.
- 319 24. Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for  
320 endometrial cancer: An umbrella review of the literature. *Int J Cancer*. 2019;145(7):1719-30.
- 321 25. Stevens VL, Jacobs EJ, Patel AV, Sun J, Gapstur SM, McCullough ML. Body weight in early  
322 adulthood, adult weight gain, and risk of endometrial cancer in women not using postmenopausal  
323 hormones. *Cancer Causes Control*. 2014;25(3):321-8.

- 324 26. Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Weight change and risk of endometrial  
325 cancer. *Int J Epidemiol*. 2006;35(1):151-8.
- 326 27. Xu WH, Xiang YB, Zheng W, Zhang X, Ruan ZX, Cheng JR, et al. Weight history and risk of  
327 endometrial cancer among Chinese women. *Int J Epidemiol*. 2006;35(1):159-66.
- 328 28. Zhang X, Rhoades J, Caan BJ, Cohn DE, Salani R, Noria S, et al. Intentional weight loss, weight  
329 cycling, and endometrial cancer risk: a systematic review and meta-analysis. *Int J Gynecol Cancer*.  
330 2019;29(9):1361-71.
- 331 29. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk:  
332 results from a systematic review and meta-analysis. *Int J Biol Markers*. 2014;29(1):e21-9.
- 333 30. Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer Risk,  
334 Prevention, and Treatment. *J Clin Oncol*. 2016;34(35):4225-30.
- 335 31. Augustin LS, Dal Maso L, Franceschi S, Talamini R, Kendall CW, Jenkins DJ, et al. Association  
336 between components of the insulin-like growth factor system and endometrial cancer risk. *Oncology*.  
337 2004;67(1):54-9.
- 338 32. Dal Maso L, Tavani A, Zucchetto A, Montella M, Ferraroni M, Negri E, et al. Anthropometric  
339 measures at different ages and endometrial cancer risk. *Br J Cancer*. 2011;104(7):1207-13.
- 340 33. La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at  
341 different ages. *J Natl Cancer Inst*. 1984;73(3):667-71.
- 342 34. La Vecchia C, Parazzini F, Negri E, Fasoli M, Gentile A, Franceschi S. Anthropometric indicators of  
343 endometrial cancer risk. *Eur J Cancer*. 1991;27(4):487-90.
- 344 35. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, et al. Metabolic syndrome  
345 and endometrial cancer risk. *Ann Oncol*. 2011;22(4):884-9.
- 346 36. Shivappa N, Hebert JR, Zucchetto A, Montella M, Serraino D, La Vecchia C, et al. Dietary  
347 inflammatory index and endometrial cancer risk in an Italian case-control study. *Br J Nutr*.  
348 2016;115(1):138-46.
- 349 37. Lucenteforte E, Bosetti C, Talamini R, Montella M, Zucchetto A, Pelucchi C, et al. Diabetes and  
350 endometrial cancer: effect modification by body weight, physical activity and hypertension. *Br J Cancer*.  
351 2007;97(7):995-8.
- 352 38. Lu L, Risch H, Irwin ML, Mayne ST, Cartmel B, Schwartz P, et al. Long-term overweight and weight  
353 gain in early adulthood in association with risk of endometrial cancer. *Int J Cancer*. 2011;129(5):1237-43.
- 354 39. Dougan MM, Hankinson SE, Vivo ID, Tworoger SS, Glynn RJ, Michels KB. Prospective study of body  
355 size throughout the life-course and the incidence of endometrial cancer among premenopausal and  
356 postmenopausal women. *Int J Cancer*. 2015;137(3):625-37.

- 357 40. Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-  
358 related cancers: a dose-response meta-analysis of prospective observational studies. *J Natl Cancer Inst.*  
359 2015;107(2).
- 360 41. La Vecchia C, Franceschi S, Gallus G, Decarli A, Colombo E, Mangioni C, et al. Oestrogens and  
361 obesity as risk factors for endometrial cancer in Italy. *Int J Epidemiol.* 1982;11(2):120-6.
- 362 42. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body mass and  
363 endometrial cancer risk by hormone replacement therapy and cancer subtype. *Cancer Epidemiol*  
364 *Biomarkers Prev.* 2008;17(1):73-9.
- 365 43. Edlefsen KL, Jackson RD, Prentice RL, Janssen I, Rajkovic A, O'Sullivan MJ, et al. The effects of  
366 postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin  
367 levels in healthy postmenopausal women. *Menopause.* 2010;17(3):622-9.
- 368 44. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum  
369 sex hormones, and breast cancer risk in postmenopausal women. *J Natl Cancer Inst.* 2003;95(16):1218-26.
- 370 45. Research WCRFAIfC. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global  
371 Perspective. Washington, DC: WCRF/AICR, 2007.
- 372 46. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen  
373 plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health  
374 Initiative randomized trial. *JAMA.* 2003;290(13):1739-48.

Age	BMI	<i>Underweight increasing to normal weight %</i>	<i>Normal weight- stable %</i>	<i>Normal weight increasing to overweight %</i>	<i>Overweight- stable %</i>	<i>Overweight increasing to obese %</i>
<b>20-30 years</b>	<b>Underweight</b>	82.60	7.22	8.78	1.86	3.10
	<b>Normal weight</b>	17.16	92.01	91.22	62.03	42.91
	<b>Overweight</b>	0.23	0.77	0.00	36.04	42.76
	<b>Obese</b>	0.01	0.00	0.00	0.07	11.23
<b>30-40 years</b>	<b>Underweight</b>	66.81	2.36	0.02	0.06	0.54
	<b>Normal weight</b>	32.11	95.13	98.79	16.67	18.99
	<b>Overweight</b>	1.01	2.51	1.19	81.91	48.21
	<b>Obese</b>	0.07	0.00	0.00	1.36	32.26
<b>40-50 years</b>	<b>Underweight</b>	44.89	1.31	0.00	0.01	0.03
	<b>Normal weight</b>	50.77	94.27	64.43	5.16	3.72
	<b>Overweight</b>	3.76	4.42	35.34	89.57	30.48
	<b>Obese</b>	0.58	0.00	0.23	5.27	65.76
<b>50-60 years</b>	<b>Underweight</b>	29.01	1.06	0.00	0.00	0.00
	<b>Normal weight</b>	60.40	93.56	16.67	2.57	0.47
	<b>Overweight</b>	8.23	5.38	78.9	87.37	12.49
	<b>Obese</b>	2.35	0.00	4.44	10.06	87.04
<b>60-70 years</b>	<b>Underweight</b>	26.56	1.02	0.00	0.00	0.00
	<b>Normal weight</b>	61.26	93.37	6.70	1.73	0.08
	<b>Overweight</b>	9.25	5.61	81.51	84.33	5.30
	<b>Obese</b>	2.93	0.00	11.79	13.94	94.62

<b>70-80 years</b>	<b>Underweight</b>	43.68	0.92	0.00	0.00	0.00
	<b>Normal weight</b>	51.67	92.95	5.48	1.18	0.03
	<b>Overweight</b>	4.00	6.12	80.47	80.28	3.36
	<b>Obese</b>	0.65	0.00	14.05	18.54	96.61

376 BMI: body mass index.

377 Table 2. Size and BMI marginal distribution over time conditioned on BMI trajectories. Italy and  
 378 Switzerland, 1988-1998.

	<i><b>Trajectory 1: Under increasing to normal weight %</b></i>	<i><b>Trajectory 2: Normal weight-stable %</b></i>	<i><b>Trajectory 3: Normal increasing to overweight %</b></i>	<i><b>Trajectory 4: Overweight- stable %</b></i>	<i><b>Trajectory 5: Overweight increasing to obese %</b></i>
<b>Size</b>	8.28	43.17	23.06	13.66	11.83
<i>BMI</i>					
<b>Underweight</b>	51.98	2.78	2.07	0.45	0.83
<b>Normal weight</b>	42.94	93.58	57.40	19.44	14.33
<b>Overweight</b>	4.06	3.64	37.50	74.15	28.53
<b>Obese</b>	1.02	0.00	3.02	5.97	56.31

379 BMI: body mass index.

380 Table 3. Description of BMI trajectories according to selected health and lifestyle characteristics and  
 381 demographics. Italy and Switzerland, 1988-1998.

		<i>Underweight increasing to normal weight %</i>	<i>Normal weight- stable %</i>	<i>Normal weight increasing to overweight %</i>	<i>Overweight- stable %</i>	<i>Overweight increasing to obese %</i>
<b>Case control status</b>	<b>Case</b>	25.58	33.66	35.53	45.68	49.47
	<b>Control</b>	74.42	66.34	64.47	54.32	50.53
<b>Country</b>	<b>Italy</b>	36.45	32.04	34.59	36.39	42.61
	<b>Switzerland</b>	63.55	67.96	65.41	63.61	57.39
<b>Age</b>	<b>&lt;45</b>	7.18	9.38	8.82	4.98	10.73
	<b>45-54</b>	15.26	19.27	17.60	19.85	19.25
	<b>55-64</b>	35.19	34.11	33.41	34.25	42.78
	<b>≥65</b>	42.37	37.24	40.17	40.92	27.24
<b>Education</b>	<b>&lt;7 years</b>	19.41	16.07	22.77	26.20	34.48
	<b>7-11 years</b>	46.54	50.04	55.27	54.79	48.76
	<b>&gt;11</b>	34.05	33.89	21.97	19.01	16.76
<b>parity</b>	<b>Nulliparae</b>	22.94	26.66	24.01	18.20	17.89
	<b>Parae</b>	77.06	73.34	75.99	81.80	82.11
<b>Age at menarche</b>	<b>&lt;12</b>	12.66	12.03	13.36	12.64	17.05
	<b>12-13</b>	37.75	40.53	42.37	45.40	41.06
	<b>14-15</b>	36.88	34.62	32.09	33.03	28.71
	<b>&gt;15</b>	12.72	12.82	12.18	8.93	13.17
<b>Menopausal</b>	<b>Pre menopause</b>	14.51	17.00	15.30	13.82	19.07



<b>status</b>	<b>In menopause</b>	5.10	6.34	6.14	7.96	6.68
	<b>Post menopause</b>	80.39	76.66	78.56	78.22	74.25
<b>Ever use of OC</b>	<b>No</b>	81.08	82.51	85.66	90.21	91.60
	<b>Yes</b>	18.92	17.49	14.34	9.79	8.40
<b>Ever use of HRT</b>	<b>No</b>	78.45	77.51	84.29	84.82	91.24
	<b>Yes</b>	21.55	22.49	15.71	15.18	8.76
<b>Smoking</b>	<b>Never</b>	63.04	65.00	73.77	77.11	68.71
	<b>Former</b>	9.92	11.61	10.76	11.12	12.98
	<b>Current</b>	27.04	23.39	15.47	11.77	18.31

---

382 BMI: body mass index; HRT: hormonal replacement therapy; OC: oral contraceptive.

Table 4. Odds ratios (OR) and related 95% confidence intervals (CI) for endometrial cancer according to BMI trajectories. Italy and Switzerland, 1988-1998.

	Overall		HRT ever use		HRT never use	
	OR <sup>a</sup>	95% CI	OR	95% CI	OR	95% CI
<b><i>Underweight increasing to normal weight</i></b>	0.52	(0.28-0.99)	0.23	(0.06 - 0.95)	0.70	(0.33 - 1.49)
<b><i>Normal weight-stable</i></b>	1 <sup>b</sup>	-	1 <sup>b</sup>	-	1 <sup>b</sup>	-
<b><i>Normal weight increasing to overweight</i></b>	1.03	(0.66-1.60)	0.33	(0.12 - 0.91)	1.55	(0.93 - 2.57)
<b><i>Overweight-stable</i></b>	1.71	(1.12-2.59)	0.80	(0.31 - 2.05)	2.19	(1.36 - 3.51)
<b><i>Overweight increasing to obese</i></b>	2.03	(1.31-3.13)	0.90	(0.19 - 4.28)	2.49	(1.56 - 3.99)

Models adjusted for age, country, education, diabetes, family history of EC, smoking, age at menarche, menopausal status, parity, ever OC use. <sup>a</sup>Model also adjusted for ever HRT use. <sup>b</sup>Reference category. BMI: body mass index.